We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. Our scalable MassARRAY System enables one-day assay turnaround times on a wide variety of targeted genetic tests, including SARS-CoV-2 detection.

Our optimized workflow helps laboratories overcome the complex, expensive, and long-turnaround challenges that come with sequencing-based technologies. Our robust technology platform along with deep customer partnership has been the foundation of our success. Identify and differentiate among the Omicron, Delta, Alpha, Beta, Gamma and other variants from the original SARS-CoV-2 lineage. Inivata, Agena Bioscience, Thermo Fisher Scientific, Guardant Health. We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease and sample integrity testing. account to trade Bio-Rad Laboratories-B stockswe will provide investors with. Owens cited the Delta variant of Covid-19, saying a collision between that and the increase in vaccinations across the world left uncertain expectations for the company economically.Īgena offers molecular testing for genetics labs and boasts of its MassArray system that allows labs to focus on a set of regions that have a known association with a disease, which can simplify the testing process.Īgena’s CEO Peter Dansky will come aboard Mesa as its new leader of the clinical genomics division. During a meeting with investors discussing its Q1 results, the company revealed that revenue increased 17% while operating decreased 13%.

Mesa’s stock price was up nearly 4.5% following the announcement.

Agena bioscience stock